摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-acetyl-2-ethoxybenzoic acid | 147676-95-7

中文名称
——
中文别名
——
英文名称
5-acetyl-2-ethoxybenzoic acid
英文别名
3-carboxy-4-ethoxy acetophenone
5-acetyl-2-ethoxybenzoic acid化学式
CAS
147676-95-7
化学式
C11H12O4
mdl
——
分子量
208.214
InChiKey
RNHCXKFXAOBPDI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    400.6±30.0 °C(Predicted)
  • 密度:
    1.196±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:8dd8a59ef83de2e9bcf9644f630c0b9d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    草酰氯5-acetyl-2-ethoxybenzoic acid正己烷 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 生成 5-Acetyl-2-ethoxybenzoyl chloride
    参考文献:
    名称:
    Method of treating a patient having precancerous lesions with phenyl purinone derivatives
    摘要:
    苯基嘌呤酮衍生物对于治疗患有癌前病变的患者非常有用。这些化合物还可以用于抑制肿瘤细胞的生长。
    公开号:
    US06200980B1
  • 作为产物:
    参考文献:
    名称:
    Mass tags for quantitative analysis
    摘要:
    本发明一般涉及用于在复杂混合物中分离和定量(差异)蛋白质的新型蛋白质修饰试剂。这些试剂与氨基酸或其他蛋白质组分或结构发生反应,并作为质量标记。本发明提供了制备蛋白质修饰试剂的方法以及利用蛋白质修饰试剂进行蛋白质定量分析的方法。
    公开号:
    US20020164649A1
点击查看最新优质反应信息

文献信息

  • [EN] BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE BENZODIAZEPINE ET COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
    申请人:ARROW THERAPEUTICS LTD
    公开号:WO2004026843A1
    公开(公告)日:2004-04-01
    Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: - R1 represents C1-6 alkyl, aryl or heteroaryl; - R2 represents hydrogen or C1-6 alkyl; - each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII is the same or different and represents hydrogen or C1-6 alkyl; - n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; - R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or, -XR6; - X represents -CO-, -S(O)- or -S(0)2-; and - R6 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C 1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C 1-6 hydroxyalkyl)-, aryl-(C 1-6alkyl)-O-, heteroaryl-(C 1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII is the same or different and represents hydrogen, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- (C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-.
    苯二氮卓衍生物的化学式(I)及其药学上可接受的盐被发现对RSV具有活性。化学式(I)其中:- R1代表C1-6烷基,芳基或杂芳基;- R2代表氢或C1-6烷基;- 每个R3相同或不同,代表卤素,羟基,C1-6烷基,C1-6烷氧基,C1-6烷硫基,C1-6卤代烷基,C1-6卤代烷氧基,氨基,单(C1-6烷基)氨基,二(C1-6烷基)氨基,硝基,氰基,-CO2RI,-CONRIRII,-NH-CO-RI,-S(O)RI,-S(O)2RI,-NH-S(O)2RI,-S(O)NRIRII或-S(O)2NRIRII其中每个RI和R...
  • Pyrazolopyrimidinone antianginal agents
    申请人:Pfizer Inc.
    公开号:US05272147A1
    公开(公告)日:1993-12-21
    Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof are selective cGMP PDE inhibitors which are useful in the treatment of such diseases and adverse conditions as angina, hypertension, congestive heart failure, reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and diseases characterized by disorders of gut motility.
    式##STR1##及其药学上可接受的盐是选择性cGMP PDE抑制剂,可用于治疗心绞痛、高血压、充血性心力衰竭、血管通透性降低、外周血管疾病、中风、支气管炎、慢性哮喘、过敏性哮喘、过敏性鼻炎、青光眼以及以肠道蠕动障碍为特征的疾病。
  • [EN] COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED<br/>[FR] COMPOSÉS, DESTINÉS PLUS PARTICULIÈREMENT À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE OU D'UNE PATHOLOGIE POUR LAQUELLE UN INHIBITEUR DU BROMODOMAINE EST INDIQUÉ
    申请人:UNIV ZUERICH
    公开号:WO2016001452A1
    公开(公告)日:2016-01-07
    The invention relates to a compound for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated characterized by a general formula (1) and a compound according to formula (3).
    该发明涉及一种化合物,用于治疗溴结构域抑制剂指示的疾病或症状,其具有一般式(1)和根据式(3)的化合物。
  • Chiral porous metal phosphonates for heterogeneous asymmetric catalysis
    申请人:——
    公开号:US20040192543A1
    公开(公告)日:2004-09-30
    Chiral porous zirconium phosphonates containing metal complex moieties are provided, synthesized via a molecular building block approach, and characterized by a variety of techniques including TGA, adsorption isotherms, XRD, SEM, IR, and microanalysis. These hybrid solids may be used for enantioselective heterogeneous asymmetric hydrogenation of aromatic ketones with remarkably high e.e. values of up to 99.2%. Similarly prepared chiral porous solids may be used for asymmetric hydrogenation of &bgr;-keto esters with e.e.'s of up to 95%. The solid catalysts can also be easily recycled and reused multiple times without the loss of activity and enantioselectivity. Ready tunability of such a molecular building block approach allows the optimization of these hybrid materials to provide practically useful heterogeneous asymmetric catalysts.
    提供含有金属配合物基团的手性多孔氧化锆膦酸盐,通过分子建筑模块方法合成,并通过多种技术进行表征,包括TGA、吸附等温线、XRD、SEM、IR和微量分析。这些混合固体可用于对芳香酮进行手性选择性的非均相不对称加氢,其对映体过量值高达99.2%。类似地制备的手性多孔固体可用于对β-酮酯进行不对称加氢,其对映体过量值可高达95%。这种固体催化剂还可以轻松回收和多次重复使用,而不会丧失活性和手性选择性。这种分子建筑模块方法的便捷可调性允许优化这些混合材料,提供实用的非均相手性催化剂。
  • Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
    申请人:Cell Pathways, Inc.
    公开号:US06562830B1
    公开(公告)日:2003-05-13
    Derivatives of 2-phenyl quinazolinones are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
    2-苯基喹唑啉酮的衍生物对于治疗患有癌前病变的患者很有用。这些化合物也可用于抑制肿瘤细胞的生长。
查看更多